Breast cancer is the most common invasive cancer in women. As per data by World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer. The changing lifestyles and the growing issue of obesity have heightened the risk of breast cancer amongst women in recent years. Therefore, the growing number of initiatives to increase awareness about this deadly disease and treat patients for this disease has boosted the growth of the global Breast Cancer Therapeutics market.
Moreover, the vastly changing reproductive patterns are also responsible for raising revenue earnings of the breast cancer therapeutics market. Again, the delayed childbearing age, reduced breastfeeding periods, intake of oral contraceptives, and resorting to hormonal therapies to solve other medical conditions are some prominent factors that contributing to the growth of the global Breast Cancer Therapeutics market. The growing awareness amongst patients about the disease and improving accessibility to premium treatments have also increased the sales of several drugs in this market. Further, effective research and development for new treatments to efficiently treat breast cancer are also anticipated to support this market development in the near future.
Covid-19 Impact on Breast Cancer Therapeutics Market
In addition, the current Breast Cancer Therapeutics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Breast Cancer Therapeutics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Breast Cancer Therapeutics Market Segment Overview
According to Cancer Type, the HER2 inhibitors is the leading segment in the global Breast Cancer Therapeutics market. During the forecast period, the HER2 segment is anticipated to expand at the highest CAGR owing to its ability to deliver accurate diagnostics. HER2 inhibitors are used in the case of metastatic breast cancer (MBC) patients who have undergone a minimum of two chemotherapeutic schedules of taxane and anthracycline. This factor is projected to increase the growth of the HER2 inhibitors segment in a significant rate throughout the forecast period.
Breast Cancer Therapeutics Market, By Drug Class
· HER2 Inhibitors
· Mitotic Inhibitors
· Anti-metabolites
· Aromatase Inhibitors
· Hormone Receptor Agonist/Antagonist
Breast Cancer Therapeutics Market, By Therapy
· Chemotherapy
· Radiation Therapy
· Hormone Therapy
Breast Cancer Therapeutics Regional Overview
Geographically, North America represented a major share of the global Breast Cancer Therapeutics market and the pattern is foreseen to continue in the upcoming years as well. The high incidence of breast cancer, supportive insurance schemes meted by the government, strong healthcare infrastructure, and growing Research and Development for novel drugs and therapies, these are key factors that majorly support the market development in this region. Similarly, Asia Pacific region is expected to have a major share of the Breast Cancer Therapeutics market in the coming years. The growing cases of breast cancer, increasing awareness about treatment, and the emerging healthcare sector are prime reasons for escalating the growth of the market in this region.
Breast Cancer Therapeutics Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Breast Cancer Therapeutics Market Competitor overview
Some key developments and strategies adopted by manufacturers in Breast Cancer Therapeutics are highlighted below.
· In September 2021, Tachyon Therapeutics, Inc., a research and development biotechnology company, announced an abstract presentation of the Company’s lead product candidate, TACH101, at the European Society of Medical Oncology (“ESMO”) Annual Meeting.
· In September 2021, Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, presented encouraging initial clinical data on samuraciclib (CT-7001), an oral and first-in-class inhibitor of CDK7, at the 2021 European Society of Medical Oncology Congress. Data presented from a Phase 2a study of samuraciclib in combination with fulvestrant in women with hormone receptor positive (HR+), HER2- advanced breast cancer (BC) previously treated with a CDK4/6 inhibitor demonstrated clinical activity and tolerability that supports further clinical development of the combination.
· In August 2021 , Laekna Therapeutics announced that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application of its Category 1 new drug candidate afuresertib (LAE002) in combination with anti-estrogen receptor drug fulvestrant in the Phase Ib/III clinical trial of patients with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Breast Cancer Therapeutics Market, Key Players
· GlaxoSmithKline plc
· Eli Lilly and Company
· AstraZeneca plc
· Pfizer, Inc.
· F. Hoffmann-La Roche Ltd.
· Puma Biotechnology
· Novartis International AG
· Sanofi S.A.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Breast Cancer Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. HER2 Inhibitors
- 5.2.2. Mitotic Inhibitors
- 5.2.3. Anti-metabolites
- 5.2.4. Aromatase Inhibitors
- 5.2.5. Hormone Receptor Agonist/Antagonist
- 5.3. Market Analysis, Insights and Forecast – By Therapy
- 5.3.1. Chemotherapy
- 5.3.2. Radiation Therapy
- 5.3.3. Hormone Therapy
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Breast Cancer Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Drug Class
- 6.2.1. HER2 Inhibitors
- 6.2.2. Mitotic Inhibitors
- 6.2.3. Anti-metabolites
- 6.2.4. Aromatase Inhibitors
- 6.2.5. Hormone Receptor Agonist/Antagonist
- 6.3. Market Analysis, Insights and Forecast – By Therapy
- 6.3.1. Chemotherapy
- 6.3.2. Radiation Therapy
- 6.3.3. Hormone Therapy
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Breast Cancer Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Drug Class
- 7.2.1. HER2 Inhibitors
- 7.2.2. Mitotic Inhibitors
- 7.2.3. Anti-metabolites
- 7.2.4. Aromatase Inhibitors
- 7.2.5. Hormone Receptor Agonist/Antagonist
- 7.3. Market Analysis, Insights and Forecast – By Therapy
- 7.3.1. Chemotherapy
- 7.3.2. Radiation Therapy
- 7.3.3. Hormone Therapy
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Breast Cancer Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Drug Class
- 8.2.1. HER2 Inhibitors
- 8.2.2. Mitotic Inhibitors
- 8.2.3. Anti-metabolites
- 8.2.4. Aromatase Inhibitors
- 8.2.5. Hormone Receptor Agonist/Antagonist
- 8.3. Market Analysis, Insights and Forecast – By Therapy
- 8.3.1. Chemotherapy
- 8.3.2. Radiation Therapy
- 8.3.3. Hormone Therapy
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Breast Cancer Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Drug Class
- 9.2.1. HER2 Inhibitors
- 9.2.2. Mitotic Inhibitors
- 9.2.3. Anti-metabolites
- 9.2.4. Aromatase Inhibitors
- 9.2.5. Hormone Receptor Agonist/Antagonist
- 9.3. Market Analysis, Insights and Forecast – By Therapy
- 9.3.1. Chemotherapy
- 9.3.2. Radiation Therapy
- 9.3.3. Hormone Therapy
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. GlaxoSmithKline plc
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Eli Lilly and Company
- 10.6. AstraZeneca plc
- 10.7. Pfizer, Inc.
- 10.8. F. Hoffmann-La Roche Ltd.
- 10.9. Puma Biotechnology
- 10.10. Novartis International AG
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
